First, FXR agonists and anti-metabolic drugs (including anti-diabetic therapies and PPAR agonists), and DNL-targeting therapies for NASH resolution, showed the highest efficacy for inflammation and fibrosis improvement. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.